It’s our last Super Stock Selectors survey for 2016, so what are the experts watching as we approach the New Year?
For the second week running, Raymond Chan of Morgans likes blood plasma and vaccines company CSL. He says the recent share price weakness, following Trump’s election victory, has been overdone.
“We see long term value here,” he notes. Switzer Super Report expert Paul Rickard has also lent his support. He feels that the both CSL and Cochlear (COH) are in the buy zone.